The demand for a therapy to counteract obesity, combined with multiple other beneficial effects on plasma triglyceride levels, fasting insulin and glucose levels, and β-cell function in diabetes, has led to the search for peripherally restricted CB1R antagonists4, 7. The gene discussed is CNR1; the disease is Obesity.